

REMARKS

I. Amendment

Claims 1-20 are pending; claims 21-56 are canceled.

Claims 1 and 3 are amended to clarify the claimed subject matter. Basis for claim 1, directed to a composition comprised of reagents is found in original claim 1 and on page 25, lines 1-14.

New claim 57 is directed to a liposome composition comprised of pre-formed liposomes and one or more targeting conjugates, wherein the pre-formed liposomes and the one or more conjugates are in individual containers prior to formation of the liposome composition. Basis for the claim is found, for example, in Fig. 1 and on page 33, lines 23-33.


New claim 58 is directed to the embodiment where the targeting conjugate is a vesicle-forming lipid-polyethylene glycol-ligand conjugate, as described, for example, on page 21, lines 23-26 and page 24, lines 1-3.

New claims 59 and 60 are directed to the embodiment where doxorubicin is the entrapped therapeutic agents. Support is found on page 17, line 2.

Accordingly, no new matter has been added by these amendments.

The Examiner is invited to contact Applicants' representative at 650-838-4402 as needed to further prosecution of this application.

Respectfully submitted,



Judy M. Mohr
Registration No. 38,563

Date: April 7, 2004

CORRESPONDENCE ADDRESS

Customer No. 22918
(650) 838-4300